- Cellectis S.A (NASDAQ:CLLS) highlighted updated clinical data on its Phase 1/2a BALLI-01 trial (evaluating UCART22) and on its Phase 1 AMELI-01 trial (evaluating UCART123).
- Compared to the last clinical update on BALLI-01 at ASH 2021, the presented data comes from five additional patients who received UCART22 at dose level 3 (DL3) 5×106 cells/kg after lymphodepletion with FCA.
- Evidence of UCART22 anti-tumor activity was observed in 60% (n=3) of the five patients.
- A patient experienced a durable, minimal residual disease (MRD) negative complete response with incomplete count recovery (CRi) that continues beyond six months.
- The company also shared preliminary data from patients who received UCART123.
- The FCA LD regimen resulted in robust lymphodepletion for greater than 28 days in all patients. Seven out of nine patients demonstrated UCART123 expansion.
- Two out of eight patients (25%) at DL2 with the FCA arm achieved a meaningful response.
- A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.
- Price Action: CLLS shares are up 8.52% at $2.42 on the last check Tuesday.
- Photo Via Company
Reported Late Monday, Pegasus Merger Co. Announces Private Offering Of $1B Of Senior Secured Notes In Connection With The Acquisition Of Tenneco Inc. By Funds Affiliated With Apollo Global Management
Pegasus Merger Co. ("Merger Sub"), which is owned by certain investment funds managed by affiliates of Apollo Global Management, Inc., today announced that, in connection the proposed acquisition of Tenneco
